Benzodiazepines: pharmacokinetic profile and clinical implications.
Major differences exist in the pharmacokinetic profile of the benzodiazepines and this provides a clinically useful basis for the therapeutic selection of compounds, particularly as anxiolytics and hypnotics. There are important differences in the elimination profile of the benzodiazephines: several factors can modify the process of oxidation appreciably; the plasma elimination half-life (T 1/2 beta) and the residual fraction (r12,1; R1, rSS) are useful pharmacokinetic parameters for evaluating the potential for persistent residual CNS depressant effects. Differences in the onset-time and duration of action are also influenced by the absorption and distribution profiles of the compounds.
D000042:Absorption; D000284:Administration, Oral; D001569:Benzodiazepines / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D001711:Biotransformation; D006207:Half-Life; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D013488:Suppositories; D014018:Tissue Distribution
D013488:Suppositories; D001569:Benzodiazepines